Efficacy and safety of port delivery platform with ranibizumab (PDS) for diabetic macular oedema (Pagoda Randomised Clinical Trial) - Takeaways - MDSpire

Safety and effectiveness of the ranibizumab port delivery system for diabetic macular oedema: the PAGODA randomized clinical trial

By
Shamika Gune
Mel Rabena
Ashwini Bobbala
October 8, 2026

Eye

Share

1

PAGODA was a randomized clinical trial of the ranibizumab port delivery system for diabetic macular oedema.
2

The provided context does not report the trial’s safety or effectiveness results.
3

Malhotra et al. presented PAGODA results at the Association for Research in Vision and Ophthalmology meeting in Seattle, Washington, on May 5–9, 2024.
4

Khanani et al. subsequently published the PAGODA results.
5

The context identifies no specific trial outcomes, adverse events, or comparison results.